What is the magnitude and mechanism of cardiovascular benefit from GLP-1 receptor agonists independent of weight loss?
Origin: "Systematic analysis of MACE outcomes across GLP-1 trials"
12,847
3,421
Nightly
2026-03-30
Epistemic Status: Validated
High confidence. Multiple evidence types. Survived adversarial review.
Revenue & Distribution
Revenue Generated
$245,000
Distributed to Contributors
$98,000
40% distributed · Tracked via Proven.dev provenance chain
Current Findings
Key Papers (2)
Cardiovascular Outcomes with Semaglutide in Patients with Obesity (SELECT)
NEJM · 2025 · Cited in evidence chain
GLP-1 Receptor Agonists and Cardiovascular Events: A Systematic Review
The Lancet · 2024 · Cited in evidence chain
Candidate Questions from Blast Radius
Does GLP-1 reduce atherosclerotic plaque volume independent of LDL?
InvestigateIs the CV benefit dose-dependent across GLP-1 agonists?
InvestigateA question rejected today is not a bad question. It might be a premature question. Like continental drift. Like H. pylori. The system remembers what it was curious about.
Oracle Schedule
Epistemic Status Scale
Related Living Queries
Help Answer This Question
Your data, expertise, or funding can help move this query from Validated to the next level.
View Campaign →What is the magnitude and mechanism of cardiovascular benefit from GLP-1 receptor agonists independent of weight loss?
Origin: "Systematic analysis of MACE outcomes across GLP-1 trials"
12,847
3,421
Nightly
2026-03-30
Epistemic Status: Validated
High confidence. Multiple evidence types. Survived adversarial review.
Revenue & Distribution
Revenue Generated
$245,000
Distributed to Contributors
$98,000
40% distributed · Tracked via Proven.dev provenance chain
Current Findings
Key Papers (2)
Cardiovascular Outcomes with Semaglutide in Patients with Obesity (SELECT)
NEJM · 2025 · Cited in evidence chain
GLP-1 Receptor Agonists and Cardiovascular Events: A Systematic Review
The Lancet · 2024 · Cited in evidence chain
Candidate Questions from Blast Radius
Does GLP-1 reduce atherosclerotic plaque volume independent of LDL?
InvestigateIs the CV benefit dose-dependent across GLP-1 agonists?
InvestigateA question rejected today is not a bad question. It might be a premature question. Like continental drift. Like H. pylori. The system remembers what it was curious about.
Oracle Schedule
Epistemic Status Scale
Related Living Queries
Help Answer This Question
Your data, expertise, or funding can help move this query from Validated to the next level.
View Campaign →